Charles Schwab Investment Management Inc. Sells 6,492 Shares of Tyra Biosciences, Inc. $TYRA

Charles Schwab Investment Management Inc. cut its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 3.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 164,108 shares of the company’s stock after selling 6,492 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.31% of Tyra Biosciences worth $1,526,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new position in Tyra Biosciences in the 4th quarter worth $60,000. Two Sigma Advisers LP purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $171,000. Deutsche Bank AG grew its stake in shares of Tyra Biosciences by 52.0% during the fourth quarter. Deutsche Bank AG now owns 18,909 shares of the company’s stock valued at $263,000 after buying an additional 6,466 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Tyra Biosciences by 21.7% in the fourth quarter. Bank of America Corp DE now owns 66,157 shares of the company’s stock worth $920,000 after buying an additional 11,804 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Tyra Biosciences by 42.7% in the first quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company’s stock worth $110,000 after buying an additional 3,550 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Up 2.4%

Tyra Biosciences stock opened at $12.67 on Monday. The firm has a market cap of $675.31 million, a P/E ratio of -7.12 and a beta of 1.09. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60. The firm has a 50-day moving average of $10.67 and a 200-day moving average of $10.28.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. Research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Piper Sandler initiated coverage on Tyra Biosciences in a report on Wednesday, May 21st. They set an “overweight” rating and a $33.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, August 22nd. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $30.83.

Insider Activity

In related news, Director Gilla Kaplan sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $10.31, for a total transaction of $309,300.00. Following the completion of the transaction, the director owned 59,623 shares in the company, valued at $614,713.13. This represents a 33.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 61,392 shares of company stock worth $628,358 over the last 90 days. 15.20% of the stock is currently owned by insiders.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.